Merck & Co Stock Price, News & Analysis

Merck (NYSE: MRK) reported positive topline results from the Phase 2 CADENCE study of WINREVAIR (sotatercept-csrk) in adults with combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).

CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary vascular resistance (PVR) from baseline at 24 weeks versus placebo. A preliminary safety assessment was generally consistent with the known WINREVAIR safety profile. The company intends to proceed with Phase 3 development and plans to present detailed results at a future scientific congress. WINREVAIR is FDA approved for pulmonary arterial hypertension and is approved in >50 countries.

Merck (NYSE: MRK) agreed to acquire Cidara Therapeutics for $221.50 per share, valuing the transaction at approximately $9.2 billion. The acquisition adds CD388, a long‑acting, strain‑agnostic antiviral in Phase 3 (ANCHOR) to Merck’s respiratory portfolio; CD388 previously received Breakthrough Therapy and Fast Track designations and showed positive results in the Phase 2b NAVIGATE study. The deal, approved by both boards, is structured as a tender offer and is expected to close in Q1 2026, subject to a majority tender, the Hart‑Scott‑Rodino waiting period and other customary closing conditions. Merck said the transaction will be accounted for as an asset acquisition.

Merck (NYSE: MRK) announced that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 20, 2025 at 9:30 a.m. ET / 2:30 p.m. GMT. Investors, analysts, media and the public are invited to listen via a live audio webcast available at the provided weblink.

Merck (NYSE: MRK) announced Phase 3 CORALreef HeFH results showing once-daily oral enlicitide decanoate reduced LDL-C by 59.4% versus placebo at week 24 (95% CI: -65.6, -53.2; p<0.001) and by 61.5% versus placebo at one year (95% CI: -69.4, -53.7; p<0.001) in adults with heterozygous familial hypercholesterolemia on stable lipid therapy.

Secondary endpoints improved: non-HDL-C -53.0%, ApoB -49.1%, Lp(a) -27.5% (all p<0.001). 67.3% of treated patients achieved ≥50% LDL-C reduction and LDL-C <55 mg/dL at week 24 versus 1.0% placebo. Safety, serious AEs, and discontinuations were similar to placebo; adherence was high (~97%). Data presented at AHA 2025 and published in JAMA.

Merck (NYSE: MRK) reported Phase 3 CORALreef Lipids results showing investigational once-daily oral enlicitide decanoate produced a 55.8% LDL-C reduction at week 24 versus placebo (95% CI: -60.9, -50.7; p<0.001) and a 59.7% post-hoc reanalysis (95% CI: -62.3, -57.1; p<0.001). Reductions were sustained at one year: 47.6% primary (95% CI: -52.7, -42.5) and 52.4% post-hoc (95% CI: -55.1, -49.7), both p<0.001. Secondary endpoints fell significantly: non-HDL-C -53.4%, ApoB -50.3%, Lp(a) -28.2% at week 24. 67.5% of patients on enlicitide met the prespecified goal of ≥50% LDL-C reduction and LDL-C <55 mg/dL versus 1.2% on placebo. Overall safety and adverse event rates were reported as comparable to placebo, with high adherence (≈97%). Data were presented at AHA Scientific Sessions 2025 (Nov 8, 2025).

Merck (NYSE: MRK) entered a financing agreement with Blackstone Life Sciences to advance development of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeting ADC. Blackstone will pay $700 million to fund a portion of 2026 development costs; the payment is non‑refundable, subject to termination provisions. Blackstone may receive low‑to‑mid single‑digit royalties on sac-TMT net sales if U.S. approval is obtained for first‑line triple‑negative breast cancer based on TroFuse‑011. Merck retains development, manufacturing, and commercialization control; the asset remains under the existing exclusive license with Kelun‑Biotech. Sac‑TMT is in 15 global Phase 3 trials across six tumor types.

Merck (NYSE: MRK) announced that Prometheus BioSciences, a Merck subsidiary, reached an agreement with Dr. Falk Pharma to discontinue their prior co-development/co-commercialization contract for MK-8690 (formerly PRA-052), an investigational anti-CD30 ligand monoclonal antibody in an early-stage clinical trial.

Under the deal Prometheus secures global rights to MK-8690; Falk will receive a $150 million upfront payment, may receive a development milestone payment, and is eligible for royalties in certain territories. Merck will record a $150 million pre-tax R&D charge (~$0.05 per share) in Q4 under both GAAP and non-GAAP.

Merck Foundation (MRK) launched the Collaborative for Equity in Cardiac Care, a $22 million initiative spanning five years to improve access to person-centered cardiovascular care in underserved U.S. communities, announced November 3, 2025.

Eleven organizations received grants to develop evidence-informed programs, and Johns Hopkins Center for Health Equity will serve as the National Program Office to provide technical assistance, peer learning, cross-site evaluation and results dissemination.

Summary not available.